Reducing Retinal Blindness Worldwide
- Retina Research Foundation
- About RRF
- Pilot Study Grants
- Grant Recipients 2024
- Samuel M. Wu, PhD
- Yingbin Fu, PhD
- Rui Chen, PhD
- Graeme Mardon, PhD
- Richard L. Hurwitz, MD
- Lih Kuo, PhD
- Wenbo Zhang, PhD
- Curtis Brandt, PhD
- Timothy Corson, PhD
- Jianhai Du, PhD
- Francesco Giorgianni, PhD
- James Monaghan, PhD
- Milam Brantley, MD, PhD
- Seongjin Seo, PhD
- Vladimir Kefalov, PhD
- Andrius Kazlauskas, PhD
- Erika D. Eggers, PhD
- Ann C. Morris, PhD
- Ming Zhang, MD, PhD
- Christine Sorenson, PhD
- Alex J. Smith, PhD
- Jeffrey M. Gross, PhD
- David M. Wu, MD, PhD
- Kinga Bujakowska, PhD
- Eric Weh, PhD
- Ching-Kang Jason Chen, PhD
- Jakub K. Famulski, PhD
- Thanh Hoang, PhD
- Georgia Zarkada, MD, PhD
- Eleftherios Paschalis Ilios, PhD
- Publications
- Grant Guidelines and Information
- Grant Application
- Grant Recipients 2024
- Research Programs
- Contact Us
- Giving
- RRF History
- Home
Murfee Chair
Kathryn and Latimer Murfee Chair
Krishanu Saha, PhD
Associate Professor of Biomedical Engineering
McPherson Eye Research Institute
Department of Biomedical Engineering
Wisconsin Institute of Discovery
University of Wisconsin, Madison, WI
Dr. Saha’s Research Project
Bioengineering of novel cell and gene therapies for the retinal disorders
Current Research Interests
Dr. Saha is a biomedical engineer who develops precision genome editing and cell therapies. He is also trained in chemical engineering.
The object of his laboratory research has been to utilize human stem cells to engineer novel cell and gene therapies. Examples include fixing inherited mutations within patient-derived, pluripotent stem cells and creating more precise tools to write the genome with CRISPR-Cas9 technology. His lab now leads several efforts in using stem cell technologies to discover and develop new genome surgery strategies (within the NSF Center for Cell Manufacturing Technologies (CMaT) and NIH Somatic Cell Genome Editing (SCGE) Initiative). With clinical partners he is building translational teams that are moving towards first-in-human trials for new gene therapy products targeting the retinal pigmented epithelium and photoreceptors in the outer retina.
